CJC-1295 No DAC — Spray

Scientific identity

CJC-1295 No DAC, formally designated Modified GRF (1-29) or [D-Ala², Gln⁸, Ala¹⁵, Leu²⁷]-GHRH(1-29) (CAS 446036-97-1; PubChem CID 91976842), is a synthetic 29-residue GHRH analogue. Molecular formula C₁₅₂H₂₅₂N₄₄O₄₂; molecular weight approximately 3,367.9 g/mol.

Compound class

Synthetic 29-residue GHRH analogue; DPP-IV-resistant GHRHR agonist; short-acting GH-axis research tool compound. Classified as a Research Use Only material and is not a drug, dietary supplement, food, or cosmetic.

Structural substitutions

Four amino acid substitutions relative to native GHRH(1-29), each addressing a specific vulnerability of the parent sequence: D-Ala at position 2 (eliminates the DPP-IV scissile site at the N-terminal Tyr-Ala bond — the primary inactivation route — without altering receptor contact); Gln at position 8 (prevents asparagine rearrangement); modified Ala at position 15 (enhances receptor binding stability); and Leu at position 27 (prevents methionine oxidation). Together these substitutions extend the functional half-life from approximately 7 minutes for native GHRH to approximately 30 minutes for Modified GRF (1-29) while preserving full GHRHR agonism.

Distinction from CJC-1295 with DAC

CJC-1295 No DAC (CAS 446036-97-1, ~3,368 g/mol, 29 residues) differs from CJC-1295 with DAC (CAS 446262-90-4, ~3,647 g/mol, 30 residues) by approximately 279 Da — a mass difference readily confirmed on the batch COA by mass spectrometry. The No DAC form has no albumin-binding capacity and a ~30-minute functional half-life; the DAC form covalently conjugates to serum albumin Cys34 and has a ~6–8 day functional half-life. These pharmacokinetic differences make the two forms appropriate for different experimental paradigms — pulsatile receptor stimulation versus sustained tonic GHRHR engagement respectively — and evidence from one should not be attributed to the other.

Primary molecular target

GHRHR (growth hormone-releasing hormone receptor) — a Class B Gαs-coupled GPCR expressed predominantly on pituitary somatotroph cells.

Product content

10mg per bottle; 45 sprays per bottle. Per-spray quantity is documented on the product label and batch Certificate of Analysis.

Physical form: Liquid research spray.

Purity: Research-grade.

Analytical documentation

A batch-specific Certificate of Analysis is available on the Longevia Research website, covering compound identity, purity, and lot traceability. Mass spectrometric confirmation of the molecular weight (~3,368 g/mol) simultaneously confirms the No DAC form and distinguishes it from the DAC-modified analogue (~3,647 g/mol). Researchers are strongly encouraged to review the COA molecular weight confirmation before use.

Research-use classification

Research Use Only. Not approved for human or veterinary use. Not intended for administration to humans or animals.

GHRH biology and research context

GHRH is a 44-amino-acid hypothalamic neuropeptide and the primary stimulatory regulator of GH secretion from anterior pituitary somatotrophs, released in episodic pulses from hypothalamic arcuate nucleus neurons and traveling through the hypothalamic-pituitary portal vasculature to bind GHRHR — a Class B GPCR coupled to Gs and adenylyl cyclase. GHRHR activation stimulates intracellular cAMP production, driving both acute release of stored GH from secretory granules and longer-term transcriptional regulation of GH gene expression. Native GHRH is rapidly inactivated in circulation by DPP-IV cleavage of the N-terminal Tyr-Ala dipeptide bond within approximately 7 minutes — making unmodified GHRH(1-29) a difficult research tool for experiments requiring sustained receptor engagement. CJC-1295 No DAC addresses this limitation through its four amino acid substitutions, particularly the D-Ala at position 2 that eliminates the DPP-IV scissile site, extending the functional half-life to approximately 30 minutes while preserving the receptor contact residues and full GHRHR agonist activity.

Pharmacological characterization and preclinical research

The foundational pharmacology of GHRH analogues in this class — including comparative receptor binding assays and DPP-IV resistance characterization — was published by Jette and colleagues (Endocrinology, 2005; PMID 15817669), who examined CJC-1295 albumin bioconjugates and the non-conjugated precursor in rat anterior pituitary assays, confirming GHRH receptor activation in pituitary tissue and providing comparative pharmacokinetic characterization between the albumin-conjugated and non-conjugated forms. In primary rat anterior pituitary cell preparations, Modified GRF (1-29) stimulates GH secretion in a concentration-dependent manner consistent with GHRHR agonism. These are in-vitro cell preparations from animal tissue characterizing pharmacological receptor activity in an experimental system; they do not establish human physiological effects. Ionescu and Frohman (JCEM, 2006; PMID 16352683) examined aspects of GHRH analogue pharmacology relevant to both forms, including the physiological significance of pulsatile GH release patterns and the experimental implications of short-acting versus long-acting GHRH analogue tools — a conceptual framing directly relevant to researchers choosing between the No DAC and DAC forms for experimental design.

Human research status and critical attribution caveat

No dedicated human clinical trial of CJC-1295 No DAC (Modified GRF 1-29) as a standalone investigational compound has been published in the peer-reviewed literature. The widely cited Teichman and colleagues (JCEM, 2006; PMID 16352683) human pharmacokinetic and pharmacodynamic study — which reported dose-dependent GH and IGF-1 responses in healthy adult volunteers — examined CJC-1295 with DAC, the albumin-conjugating form. Its findings apply specifically to that compound and cannot be attributed to CJC-1295 No DAC, which is a structurally and pharmacokinetically distinct research compound. CJC-1295 No DAC is not approved for human therapeutic use by any regulatory authority and has no approved human indication. Longevia Research supplies this compound for laboratory research use only.

For a tetrasubstituted 29-residue GHRH analogue, analytical quality documentation addresses compound identity at the sequence level and chromatographic purity — distinguishing the correctly modified research material from the unmodified parent sequence, from alternative CJC-1295 variants (particularly the DAC form), and from truncation or deletion impurities that can arise during solid-phase synthesis of proline-containing sequences.

Identity confirmation: Each production lot of Longevia's CJC-1295 No DAC spray is characterised by mass spectrometric analysis, verifying the observed molecular ion against the expected mass for Modified GRF (1-29) at approximately 3,367.9 g/mol (C₁₅₂H₂₅₂N₄₄O₄₂). This confirms the compound is the No DAC form and is not the DAC-modified variant (~3,647.25 g/mol), which would be clearly distinguishable by the ~279 Da mass difference.

Purity assessment: Chromatographic purity analysis quantifies the target compound relative to all UV-absorbing species in the chromatogram. For this compound class, purity documentation is particularly important because the research market's history of confusion between CJC-1295 forms means that molecular identity — not just purity percentage — is the critical analytical specification.

Batch traceability and Certificate of Analysis: Every production lot of CJC-1295 No DAC 10mg spray is traceable to a specific batch. A batch-specific Certificate of Analysis is accessible on the Longevia Research website, covering compound identity, purity, and lot information. Researchers are strongly encouraged to review the batch documentation — particularly the molecular weight confirmation — before use, to confirm they have the No DAC form.

Storage: Specific storage conditions for this lot are confirmed on the batch Certificate of Analysis and product labelling. Researchers should follow the COA's lot-specific guidance and institutional protocols for synthetic research peptides.

Longevia Research supplies CJC-1295 No DAC 10mg Spray for laboratory and in-vitro research use only. The product is intended for qualified researchers and trained laboratory personnel working in appropriate controlled research environments.

CJC-1295 No DAC (Modified GRF 1-29) is a synthetic research peptide supplied strictly as a laboratory research tool. It is not CJC-1295 with DAC; these are distinct compounds with different molecular structures, different CAS numbers, and different pharmacokinetic profiles, and they must not be treated as interchangeable. It is not a drug, not a dietary supplement, not a food or food ingredient, and not a cosmetic. No regulatory authority has approved CJC-1295 No DAC for human or veterinary therapeutic use, and Longevia does not supply this product for administration to humans or animals, for clinical diagnostics, or for any therapeutic application.

No therapeutic, diagnostic, or efficacy claims are made for this compound. The scientific literature referenced on this page describes experimental observations from defined cell-based and animal model systems, and from human research conducted on the structurally distinct CJC-1295 with DAC compound — findings from the DAC form do not apply to this product. No dosing instructions, spray-frequency guidance, administration protocols, or cycle recommendations are provided. The purchaser assumes full responsibility for lawful acquisition, handling, storage, use, and disposal of this material, and for compliance with all applicable local, state, federal, and institutional regulations.